Clinical Trial Update: Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Sonrotoclax and Zanubrutinib in relapsed/refractory Mantle Cell Lymphoma patients who are planned to receive standar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Sonrotoclax
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING